Abstract
33
Objectives: Our aim in this study is to evaluate non-diagnostic computed tomography (CT) images obtained for attenuation purposes and single photon emission computed tomography (SPECT) images in myocardial perfusion scintigraphy (MPS) in patients with a history of COVID-19 known.
Methods: The information of 287 patients who had MPS imaging with pharmacological stress in our department between October 2020 and January 2021 were retrospectively evaluated from the hospital information system. The patients were divided into two groups according to the only ground glass density on CT and the presence of Tc-99m methoxy isobutyl isonitrile (MIBI) involvement with ground glass density. The date when the patients were diagnosed with COVID-19 was recorded.
Results: Twenty-two patients had a history of COVID-19. There was an average of 74±46 (15-186) days between the diagnosis of COVID-19 and MPS. Ground glass density was observed on non-diagnostic CT in 11 patients. Ten patients had increased Tc-99m MIBI uptake consistent with ground glass areas. The median time between diagnosis and MPS was calculated as 50.5 days in patients with Tc-99m MIBI involvement in the lung and 63.5 days in patients without involvement, but according to the time interval between diagnosis and MPS, there was no significant difference between them (p> 0.05).
Conclusions: Although imaging models corresponding to clinical improvement in patients diagnosed with COVID-19 usually occur after the 2nd week of the disease, they may continue for a long time after the diagnosis, moreover, increased radiopharmaceutical uptake may accompany this. Keywords: COVID-19, MPS, MIBI
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.